Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) https://validator.w3.org/feed/docs/rss2.html IMMUNOLOGY SEMINAR: PEPTIDE CANCER VACCINE EXPERIENCE AT NCI Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) Antibody-Drug Conjugates (ADCs) – Recent Advances in the Treatment of Solid Tumors Patient Care and Toxicities Management of CAR T-cell in Pediatrics Affordable Immunotherapy: Opportunities and Challenges International Summit on Cellular Immunotherapy 2026 | SCT-PSU x TTCI Operational Readiness, Safety, and Quality Management for ATMP Clinical Trials in Thailand Antibody-Drug Conjugates (ADCs): Recent Advances in the Treatment of Solid Tumors Effective CAR T-cell targeting of an MUC1 cleavage product TTCI Showcases Emerging Immuno-Oncology Talent and Invites Global Community to Thailand for WIC-APAC 2027 CAR T-cell Immunometabolism: Insights from Patients A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma. A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma. Division of Hematology, Department of Medicine, Faculty of Medicine Thammasat University Stem Cell and Molecular Biology, Center of Excellence in Stem Cell Research and Innovations, Faculty of Medicine, Thammasat University Department of Paediatrics, Faculty of Medicine, Thammasat University Member Contents Our Team Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy Division of Cell Biology, Department of Preclinical Sciences, Faculty of Medicine, Thammasat University On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy in glioblastoma models Basic Cancer Immunology for Clinicians AP-SciBio 2027 x WIC APAC 2027 & Thai Immunology Annual Meeting A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement Personalized Cancer Vaccines – A New Frontier in Thailand’s Fight Against Cancer Government Agencies and Related Announcements Cell Therapy for Solid Cancers: Promise or Overpromise? CAR T-cell therapy for paediatric solid tumours: clinical trial development and preclinical modelling TTCI to Participate in WIC-APAC 2026 CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML TTCI at a glance Chiang Mai University Team Mahidol University Team Affordable Immunotherapy – Opportunities and Challenges NRCT Hosts Seminar on “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment” at MHESI Fair 2025 International Collaborator Pediatric Neuro-Oncology Consortium – Chulalongkorn University Research Forum Thai Immunology Annual Meeting 2026 White Paper IPOPI | SEAPID | Chulalongkorn | Erasmus MC Meeting 2026 Scientific Meeting: Medical Applications of Gene Editing and Synthetic Biology Technologies On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy in glioblastoma models TTCI Webinar “CAR T-cell Immunometabolism, Insights from Patients” Cell Therapy for Solid Cancers – Promise or Overpromise? Thailand Successfully Hosts Its First WIC APAC Webinar, Drawing Strong Regional Interest in Personalized Cancer Vaccines Thammasat University Team TTCI Representative Highlights CAR-T Cell Therapy Roadmap at the 74th JSTMCT Annual Meeting in Yokohama Chulalongkorn University Team Registration Open: 1st International Scientific Symposium in Hematologic Malignancy (CETH, Chulalongkorn University) TTCI Researchers Present and Collaborate at the 29th Annual Meeting of the Japanese Association of Cancer Immunology